TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Syntara Limited ( (AU:SNT) ) has provided an announcement.
Syntara Limited has made significant advancements in its clinical programs, particularly with its lead therapy, amsulostat, which has shown promising results in treating myelofibrosis. The company has received positive feedback from the US FDA and a supportive opinion from the European Medicines Agency, enhancing its regulatory positioning. Additionally, Syntara is expanding its clinical reach into myelodysplastic syndromes and dermatology, with ongoing trials in hypertrophic and keloid scarring. Financially, the company remains stable, supported by disciplined cost management and non-dilutive funding, allowing it to progress multiple studies in parallel.
The most recent analyst rating on (AU:SNT) stock is a Buy with a A$0.06 price target. To see the full list of analyst forecasts on Syntara Limited stock, see the AU:SNT Stock Forecast page.
More about Syntara Limited
Syntara Limited is a company focused on developing first and best-in-class therapies for serious diseases driven by fibrosis, inflammation, and malignant bone marrow dysfunction. The company is involved in clinical programs addressing fibrosis, inflammation, and neurodegeneration, positioning itself strongly in the pharmaceutical industry.
Average Trading Volume: 2,683,659
Technical Sentiment Signal: Sell
Current Market Cap: A$50.6M
For detailed information about SNT stock, go to TipRanks’ Stock Analysis page.